The MiniMed 630G system gives you the control you need for the lifestyle you want:
|MiniMed® 630G system||MiniMed® 670G system||Pumps from other companies|
|NEWLY approved attractive and user friendly pump design for ease of use||•||•||•|
|Bright color screen with auto-brightness for easy readability – day or night||•||•||•
|Waterproof design§ for greater protection during underwater activities||•||•||•
|Remote insulin delivery for added discretion||•||•||•
|Built in CGM so you can make informed decisions||•||•
New Guardian sensor 3
|SmartGuard Technology suspends insulin for added protection when lows occur1,*||•||•||•|
|SmartGuard Technology suspends insulin for advanced protection before lows occur*||•||•
New SmartGuard HCL Technology
|SmartGuard Technology automates insulin delivery based on CGM readings to help maximize your time in range||•||•
New SmartGuard HCL Technology
|24-Hour helpline team – available around the clock for help and support||•||•||•
Are you using another brand of pump?
Click here for a special offer.
Want to be first in line for the new system?
Purchase a MiniMed 630G system today, and get the MiniMed 670G system for just $799. Experience our newest pump platform now for a smooth transition to the MiniMed 670G system, available in spring of 2017.
As a valued customer, you will bring your total out-of-pocket cost down to only $299 when you send back your MiniMed 630G pump and transmitter for a $500 exchange.
Limited time offer: Your final cost for the MiniMed 670G system could be $0** if you participate in an approved system access program.
This offer is available to all new and existing Medtronic customers who purchased a MiniMed 630G system (pump and CGM) between August 10, 2016 and April 28, 2017.
Get started on the MiniMed 630G system today to secure your priority access to our newest technology.
Speak with one of our Diabetes Therapy Consultants today!
* Measured as sensor glucose values.
** For a limited time until April 28, 2017, your Priority Access program out-of-pocket cost could go as low as $0 if you purchase a MiniMed® 630G system and participate in an approved system access program. Additional terms and restrictions may apply.
† Normal restrictions for the Priority Access program still apply. Additionally, once the new technology is commercially available, patients will need to acquire a prescription from their physician and verify that their payer will support transitioning to new Medtronic technologies, as it could affect ongoing coverage of their current and future pump and/or monitoring supplies.
†† Purchase of the MiniMed 630G insulin and pump transmitter is required. Normal restrictions for the pathway program still apply. Additionally, once the new technology is commercially available, patients will need to acquire a prescription from their physician, and verify that their payer will support transitioning to new Medtronic technologies as it could affect ongoing coverage of their current and future pump and/or monitoring supplies.
¶ Assumes four injections per day for 30 days and one infusion set change every three days.
§ The pump is protected against the effects of continuous immersion in up to 12 feet (3.6 meters) of water for up to 24 hours at a time at the time of manufacture. This is classified as IPX8 rating. See user guide for more details.
1 Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–232. Study focused on nocturnal events and conclusions reached subject to limited sample size and duration.
Important Safety Information: MiniMed® 670G System
The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed 670G System consists of the following devices: MiniMed 670G Insulin Pump, the Guardian Link (3) Transmitter, the Guardian Sensor (3), One-press Serter, and the CONTOUR NEXT Link 2.4 Glucose Meter. The system requires a prescription.
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
WARNING: Do not use the Suspend on low feature to prevent or treat low glucose. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional to treat low glucose. Using Suspend on low alone to prevent or treat low glucose may result in prolonged hypoglycemia.
WARNING: Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.
Guardian Sensor (3) The Guardian Sensor (3) is intended for use with the MiniMed 670G system to continuously monitor glucose levels in persons with diabetes. It is intended to be used for detecting trends and tracking patterns in persons aged fourteen years and older, and to be used by the MiniMed 670G system to automatically adjust basal insulin levels. It is indicated for use as an adjunctive device to complement, not replace, information obtained from standard blood glucose monitoring devices. The sensor is intended for single use and requires a prescription. The Guardian Sensor (3) is indicated for 7 days of continuous use.
The serter is used as an aid for inserting the sensor. It is indicated for single-patient use and is not intended for multiple patient use.
Guardian Link (3) Transmitter
The Guardian Link (3) Transmitter is intended for use with MiniMed 670G System. The Guardian Link (3) Transmitter powers the glucose sensor, collects and calculates sensor data, and wirelessly sends the data to the MiniMed 670G insulin pump. The Transmitter is intended for single-patient multi-use.
CONTOUR®NEXT LINK 2.4 Glucose Meter
The CONTOUR®NEXT LINK 2.4 Wireless Blood Glucose Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single patient use only and should not be shared. The CONTOUR®NEXT LINK 2.4 wireless blood glucose monitoring system is indicated for use with fresh capillary whole blood samples drawn from the fingertip and palm only. The CONTOUR®NEXT Test Strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL. The CONTOUR®NEXT LINK 2.4 wireless blood glucose transmit glucose values to the MiniMed 670G insulin pump and facilitate transfer of information to Medtronic CareLink® Software through the use of radio frequency communication. The CONTOUR®NEXT LINK 2.4 Wireless Blood Glucose Monitoring System is not intended for the diagnosis of, or screening for, diabetes mellitus. It is not intended for use on neonates.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products. Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.
For additional information, please consult the appropriate User Guide.
Important Safety Information: MiniMed® 630G System with SmartGuard™ technology
The MiniMed 630G system with SmartGuard™ technology requires a prescription. It is intended for continuous delivery of basal insulin and administration of insulin boluses for the management of diabetes mellitus in persons 16 years of age or older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The SmartGuard feature allows one to program the pump to temporarily suspend delivery of insulin for up to two hours when the sensor glucose value falls below a predefined threshold value. The MiniMed 630G system is not intended to be used directly for making therapy adjustments or preventing or treating hypoglycemia. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare professional. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter (BGM). A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 Meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always’ send mode. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day, or who are unwilling or unable to maintain contact with their healthcare professional, or whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use U100 rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. WARNING: The SmartGuard Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set limit. Under some conditions of use the pump can suspend again resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard Suspend on low feature, it is important to read the SmartGuard Suspend on low information in the Getting Started Guide and the MiniMed 630G System User Guide and discuss proper use of the SmartGuard Suspend on low feature with your healthcare professional.
Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
Go to medtronicdiabetes.com/importantsafetyinformation to review the important safety information.
MiniMed is a registered trademark, SmartGuard is a trademark of Medtronic, MiniMed Inc.